Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.

Oncotarget

Volumn 1, Issue 7, 2010, Pages 530-543

  Markman, Ben ^a   Dienstmann, Rodrigo ^b   Tabernero, Josep ^b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; EVALUATION; HUMAN; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 79957983577     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.188     Document Type: Review

References (0)